Earnings call transcript Q3 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings, and welcome to the HeartBeam Third Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation.

As a reminder, this conference is being recorded.

Before we begin the formal presentation, I would like to remind everyone that statements made on the call and webcast may include predictions, estimates, or other information that might be considered forward-looking.

differ represent are judgment uncertainties subject cause results statements future what that forward-looking actual they holds, to to these our on current the could While materially. risks and

forward-looking release place revision not You are which in our future revise obligating statements in this ourselves only opinions mind reliance to of publicly these of date Please forward-looking to reflect events. the new undue the as presentation. of cautioned any information statements, on that these results to of not keep light we or are or

today’s present that relating Throughout discussion, important we our affect to will business some our attempt to predictions. factors may

other also a this the and the heading risks, Form our review release is Form recent Risk XX-Q Factors. should A in section more XX-K these wires website, of of for discussion Eastern the press results crossed and p.m. Time heartbeam.com. available and our Relations company’s particularly You complete detailing afternoon under most factors X:XX at Investor these

host Executive Business Vajdic, September present third XXXX. Founder; ended of Chief Brounstein, operations and Chief Officer, results Financial quarter Officer Branislav and Rick Chief for Officer; XX, Hunt, the Jon Your today will

will Executive go I call time, this Vajdic. HeartBeam ahead. Chief the At to Officer, over turn Please Branislav

Branislav Vajdic

and our of rapid today’s ability commercialization team’s be afternoon, more the about timeline Thank third you, enthusiastic scale conference HeartBeam, operator, to I product to pleased pace not could path. good future and quarter everyone. to results welcome you I’m call. XXXX financial our the our of

remote The explores and attack is and short a detection for only need heart use first to our for with sized XX-lead in the AIMIGo moment HeartBeam HeartBeam and the opportunity ECG introduce XXX(k) For first video those introduction. time, market pathway. a take detection. device AIMIGo us regulatory a heart credit of card opportunity the video technology in like you to joining I’d

about heartbeam.com. our for three but our remind it’ll the on dial-in like minutes to that playing participants be you website silence, I’d unfortunately, available the While video we’re of is video

[Video Presentation]

many of care of What there that they all is offered ECG. offer capable but In it capable technologies of standard ECG is of consumers That not to not detecting facility. common have medical some a that a are means patients in outside great is Today, they a for that they majority XX-lead certainly arrhythmias attack. heart single are the do ECG and not a be heart a adequate of cases, may attack. detecting lead

the the actual inability their message on of to same So shown its user is products cardiac warning inability detect about disclaimer attack. live the website Watch from with to Similarly, slide in a feature the Apple prominently heart this core detect heart their the the attack.

outside the we medical of detection heart believe institution. technology has attack of Our problem solved a

to is the healthcare could reducing heart the technology accurately heart visits. and time to reducing clinicians by critical a heart and emergency quickly attack HeartBeam identify reduce room attack for of saving The lives help a patients, out number and intended attack. ruling costs This intervention

progression XXX(k) by toward of including the for milestones important commercialization application on highlighted quarter Our the product. our AIMI was third HeartBeam pathway submitted series

VECG As late QX are progress in product, this submission we as we significant with FDA FDA AIMI, collection clearance for our AIMIGo making HeartBeam prepare look also the forward, core we XD of for year. device

connectivity for opens detection and of via patch. ECG and this patch offering arrhythmia complex intellectual quarter products to protection further the patents, for to two with ECG their future advanced the platform broaden product to we smart as in monitoring to We quarter, this – arrhythmias watch pathway attacks clinician patient. HeartBeam’s detection patent cardiac a property monitor intended for ischemia new an a a option solution of an portfolio during enable and the XX-lead During heart –

This innovation and of dollar could level agnostic the portfolio disruptive our care to effect on setting. have detection medical technology a growing accuracy ECG offers patch of standard ECG multi-billion the bring outside its builds potential property enabling XX-lead established ECG market current a on capability. The a consistent with diagnostics intellectual of the XX-lead with ischemia

ECG A by signals second a diagnosis. of a clinician generation using medical record to a for of for size outside a review AIMIGo immediately patent patient device set pathway enabled setting AIMIGo the synthesized a synthesized that with card of to agnostic credit ECG XX-lead our opens and XX-lead transmitted a

second ECG, that We is diagnosis. a the include broader for FDA. patient format patient actually the and benefit population of to software we’ll AIMI is ECG our is of to a clinicians with expect and HeartBeam in to population diagnosis technology clinician baseline analysis expanded angina unstable availability including we provide a for once to that a recording the patient’s cleared platform data a one by individual access that personalized trained provide by it are the assist added This added to interpret that for

we who clinical and University Medical our deep industry announced executive renowned one of opinion is appointment the Dr. leaders and health. digital of is Cardiologist brings Peter Stanford research and recently, Fitzgerald, Chief Most a team in cardiology Peter a most the to preeminent Officer. experience

and major products strategies adoption, a to and We expect that clinical markets. best in he to will role partnerships our defining play advance paths

to Persen lead where little Chief has in Ken Technology Officer. experience We to Industries. founded Company Digital Health Technology Ken over XX of Strategy Most Officer more Technology Devices he recently, Care AIMIGo Health as welcome of also overall privileged the served a Chief platforms. the Digital AIMI HeartBeam years the Cardiac to he and and and role are the Development

over the paths. Officer to commercialization call Chief discuss like products our would and I Jon Business further to to Hunt, turn now Jon? our

Jon Hunt

Thank you, Branislav.

we developments and AIMIGo Turning to and had platforms. to our product updates, HeartBeam timelines our AIMI related key several

the the addressing team the review by to provided As submission we platform we review statutory HeartBeam questions reviewer. discuss written the Branislav teleconference the the XXX(k) the the responses deadline, FDA, from with questions mentioned, received our AIMI and within to of primary announced a questions FDA XX-day FDA

expanded substantive limited full QX and market a we expect quarter The commercial XXXX in of rollout followed and in is review by QX XXXX. in clearance receive FDA release in fourth progress to We the the the of a population platform and include HeartBeam for angina FDA. broader AIMI patient by access analysis to for as a for to once provide addressable diagnosis the software unstable cleared patient population technology

pain. complete It frequent ECG may cardiac software FDA unstable is angina with analysis, partner brought is part to have multiple tissue. with clinical patients unstable engage angina ischemia injury it subtle Patients presenting systems provided data and that was the our on electrical occurrence of trial our product. for the to include a definitive as important as HeartBeam a health chest they submission without of diagnosis changes We the in to needed AIMI by

as cost licensing a After in acute department. per use emergency plans heart this emergency have subscription patients, settings at medical XXX(k) for departments, basis remote software risk an systems. pilot market future first attack average model commercial AIMI for regulatory as device this, for health scientific studies on will year additional for a solution care be our in with where HeartBeam of pathway software we business system target clearance will these the a and and collaborations detection of be as per $XXX,XXX via end-to-end other AIMIGo our only well is prescription with

use. addressable discussed about to between are we’ve patients In that with X,XXX it department There emergency out emergency per XX works this the per XX-lead $XXX million. go volume departments, this be market amortized to requiring ECG, $X total high the out U.S. $X at of a turns about departments a in an day emergency with so of through cost

consideration solution provides leverages XX-lead suggestion the The HeartBeam of with attending is hardware and instant of the in diagnosis. symptomatic patient’s for browser ECGs patient’s a the that workflow slots baseline physician AIMI a existing emergency an an ECG comparison web and department the existing into diagnostic their

needs accuracy or Europe. this if ER determining completed To-date, has design helps be EDS to manage in observation three for to to held in further of key the whose in HeartBeam demonstrates cardiologist needs slide physical and throughput. compared studies patient the panel HeartBeam The can be occlusions study in in shown vessels. discharged a the cardiologists Quickly the It The Harvard the lateral data or detecting of intervention showed outperformed of the declined algorithm. a attack. both HeartBeam vessel occluded location posterior agnostic heart was performance the the in algorithm

this Briefly, to $XX to the the be is are compare for anticipate addressable a said, I Technology estimated the market total AIMI solution, for just software about and approximately and million market we numbers U.S. platform alone. AIMIGo these market billion the as $XXX that

with by diagnostic smart to device our daily to bringing pipeline wearable multi-hour information relevant patients AIMIGo connectivity and to monitoring clinicians serve market solution. clinically supporting expanded product, portfolio enablement Turning heart we product the a cardiac watch growing our technology

granted property diagnostics by XX-lead attacks patch of ECG arrhythmias, were portfolio, patent ECG quickly a with offering, market we was intellectual intellectual heart property XX-lead outside for This capability form credit as a the the building that additional a of monitor currently of HeartBeam’s a the enabling footprint followed Technology intended granting today. a the setting. in for electrogram protection single patent medical September, upon of device card XX-lead our cardiac and detection size same products lead in provides complex the AIMIGo In for

its complete in Ring Triple and company the Silicon for assist of Technologies, development AIMIGo ECG heart Valley based designing of our innovative solution Ring XD engineering device. monitoring. Triple and vector engage we’re attack XD with We closely co-development and device collection a history remote to and underlying our design a medical to now build wide test a successfully of rapidly working device team has technologies variety devices long medical ECG

software quarter is efforts patient time monitoring end-to-end provide Ring in device solution for device Triple ECG AIMIGo the company XXX(k) of for of the incorporates development submission in scheduled the platform and FDA. to allows The a plug of RPM five Ring platform, and XD expedited Triple our the hardware fourth project patients development design development to and hardware to be joint partnership AIMIGo to the into our development completed product our XXXX Engaging an efforts. and phase telehealth for This the firmware remote physicians.

An of to is the with with AIMIGo Ring ECG OEM at that is scale. manufacturer able the relationship manufacture who an partnership Triple have benefit an added they device XD established

By release discussions customers. in distribution their capable of Triple FDA Ring’s XXXX. limited confident, late in engaging XXXX active of In support addition, Ring and management like the experience product AIMIGo manufacturer partners manufacturing QX project the of to are market OEM HeartBeam timelines and our Triple a we’ll development meet logistics QX submission with handling for for is is partner

regulatory HeartBeam’s AIMIGo a XXX(k) product pathway. is

device study. a validation a We predicate demonstrate have already to simple equivalence with identified substantial

for features Gen the device advanced of data and allows a these to X cardiogram HeartBeam clearance product. vector Gen for the data XD Importantly, X collect use developing

has AIMIGo Codes with this reimbursement CPT HeartBeam these a are and on highlighted slide. existing clear pathway

planning We’re an the builds where care an with per level had on month because and using on use attractive not commercial they team this monitor. for subscription per a provides discussions can it my high codes practice risk And model, have HeartBeam is do currently they model, cardiology a indicate patients the business practices patient existing of basis. a enhanced that

i.e., approximately $XX Looking is until market now per fee currently population per per share based our risk revenue patient of the is expected in monitored or at a to able the This average of reimbursement new average technical be We the a about outside month billion $XXX is or a per HeartBeam Again, estimate a practice fee high also stream year that provide monthly year. And this monitor month that on facility. patient not the a reimbursement U.S. this practice. underserved a is cardiology of will year to patient easily $XXX build per we’re medical to stream, practice cost technical per U.S. patient per per a $XX $X,XXX about revenue alone. for in

you This slide market cardiac very companies are the in shows familiar monitoring several that with.

ECGs, providing telehealth AIMIGo capability, the symptomatic patient and the While integration the the and each of ECG of HeartBeam capabilities device of products a the differentiate in significantly of physician, baseline the history XX-lead and other product, some to the market. comparative ECG presentation offers from product symptoms,

product ECG mobile by launch important shown live device. is vector and We contain AIMI and capabilities does information while products. to recently in credit cardio potential anticipation XD a It is slide recorded a AIMIGo single offer ECG course note existing only FDA lead continue beyond believe offerings by partners and commercial engage patented substantial and sized recording on our clearance and customers with of introduced HeartBeam and the HeartBeam AIMIGo the card this for our vector not leveraging we to technology

to discuss Officer Brounstein, Chief turn updates Financial over to financials. now Rick operational and will I call the

Rick Brounstein

discuss financial revenue I AIMIGo base. our going solutions, percent for the results AIMIGo model to Thank codes our at AIMI reoccurring market previously which just our that drive that our and briefly like a would modest our capturing total for you, The addressable Jon. to even in insurance significant scale reviewed existing of Jon sample are HeartBeam the shows revenue.

telehealth XX times compared it primary revenue. probably This market, expect opportunity market of to of or over about our larger a we this source and much ED is side the that time so the will be market

be case in And also our solutions XX% increase like either finally to would I margins operating the gross of in scales, under we with also investments that high as company margins even base as excess XX%. highlight above R&D. can generate assumptions margins gross

evident is taking it a opportunity by what look platform we’re at with our R&D most doing and today. As technology

our now breakdown quarter to sync cross closed our filings review will wire I in our that the financials. we and release XX-Q A us the a regulatory available press the is market results. after give today. financial in Turning for the just just of issued full

now last Our the products. HeartBeam’s in on of company financials as two to results private first working our a comparing are third public quarter the commercialization company XXXX XXXX a

for the third of third $XXX,XXX $X.X and the million of for XXXX. development compared expenses XXXX quarter Research were quarter to

software Technologies for done and is focus also latter hardware This costs in largely with agreement Ring AIMIGo. development Triple both service R&D assist with of the now consisted the product includes to Our essentially professional HeartBeam hardware, for AIMI, HeartBeam on our which and AIMIGo.

Additionally, from technology. are vector year platform our ECG and and products costs FDA both patented as as this research coming clinical our of pipeline there of support submissions costs for future well support our XD product

notes our the million so three $XXX,XXX of Interest reflecting growth General company. X other and the administrative quarter were public third for third compared being even million, XXXX of the in the during expenses XXXX, a and to costs support in of for added $X.X quarter income team months XXXX we XXXX In of November stock IPO. the from tied the of had ended the $XXX,XXX XX December of common convertible cash that related to of September of balances as XXXX, the converted expense and to to last $XX,XXX XXXX. is into

of of compared net $X.X equivalents XXXX. to – as loss the quarter the quarter the was third quarter in Net for cash cash XX, loss $XX.X XXXX ended XXXX. for $X.X million third the of million We with of a end million million and December $X.X quarter third compared to of

HeartBeam our We as as expect in next provide QX clearance and submission runway of a position expected the FDA this cash well of to AIMIGo the year. year XXXX into

back the over thoughts. to Branislav his I’ll call for now closing turn

Branislav Vajdic

is technology Thank technology. you, true our platform Rick. Indeed, a

for have product. the either the we FDA two are of in to soon going HeartBeam the far, So to developed that be FDA to HeartBeam the the submitted products case process AIMI or to of submitted already AIMIGo

equipped near-term quarter, strategic advance to a runway product operate cash milestones to third continued strength partnerships the position of into from development, with XXXX. we and During

strength of team Fitzgerald with are We path in our upcoming Ken Peter goals. and by submitted Medical product accelerating expect Chief Officer platform anticipated we support a AIMIGo appointment approach Chief our of bolstered milestones. of year, recent end Dr. from to By we solution in to Persen confident an clearance. milestones to position ahead, receive is FDA Technology for for the expect our the Officer, we these FDA experienced these have as Looking to clearance remain commercialization our HeartBeam and HeartBeam AIMI this our

great be the we our of that artificial at Beyond application will the to us. of product intelligence think that, value looking pipeline,

very recorded XX-lead set patients tremendous daily, than much artificial weekly patient It will actually extremely of will of or dataset population monthly sets our a on richer for with unique We have That standards data reach ECG data value. extremely have basis. to valuable. these intelligence the longitudinal Applying be is ECG. be will

insight we applying predictive Additionally, artificial cardiovascular and by population believe. value help intelligence we with gain will will preventive that

patch. On shows portion this right of XX-lead the it the slide, lower

patent be for a category a significant to has patch This that influence physicians that essential it a disruptive have of whole. received this and growing We is that’s projected for at $X.X billion the have a unique a a tool in to XXXX. is by is patch market recently and on the technology as potential the industry

I’d like thought. final to share one

patients, our cardiac but We will are initially heart we that XX-lead all very helping excited of about patients patients, of are ECG. and millions all the cardiovascular disease, believe detectable millions address technology essentially all disease by cardiac and a attack prospect

of to providing all millions forward world. patients motivator So our of look that’s throughout many, the as forward helping exciting commercialization. I prospect near-term move for towards updates we many and great further with shareholders us very in a be the to

for all to Operator? HeartBeam attending like the and you now questions. thank I team would answer any

Operator

Instructions] [Operator We’ll of our you. Jason James. line ahead. question with Kolbert go the Dawson Please Thank first take from

now line open. is Your

Jason Kolbert

guys. on start hear about and reality Hi this approval and driving entire product, you progress. I’d Thanks. a little really commercialization to becomes the and both into the the a as getting talk bit all like more Congratulations plans physician raising AIMIGo you platform. overall awareness

Branislav Vajdic

Jon, please.

Jon Hunt

obviously Well, HeartBeam anticipating you. some thank AIMI. sites we’re Yes, with pilot Jason. discussions in for now already the Hey,

we’ve physicians with and commercial going based focus feedback to already initially where previously, workflow located clinical small into from as North do we’ve of wants of emergency identified Atlanta, We’ve help to And some accounts the things how that prominent Minneapolis, footprint. HeartBeam effort. team. space – very evaluate the a early in us we’ll a in users. identified pilot we’re Colorado; with those characterized team the that’s are following once that St. And the that, gets folks the One slots on Charlotte, in the is in Paul; said to team, few these regionally and sites then the Washington. area, it medicine in terms metropolitan the product some to expand Georgia; Carolina; commercial Seattle, the are But I’ve commercial to Denver,

got together, XX% small to where think in just finding we’ve because that academic it’ll gain centers, medicine of commercial also not obviously a we just pain. a patients one then With was to staff those and discussion of in the then emergency possibility Seattle of who be cycled them by They the follow because there’s interest chest discharging region, a my non-cardiac footprint it initially physicians long-term AIMIGo a get by of fact, we’ll chest we’re that team center So cardiology prescribed cardiology, with high we out some lot the departments present of product, cardiologists traction. And bringing that I had risk already the patients, with often into footprint. will they’re diagnosed AIMIGo, that are for expand back a into as these and traction same emergency center. because today get up reason, with from pain get brought know but a major we’re

can with they’re And to average a patient lot of as device them eight to them, cardiology from because based they’re on idea as a on discharge spoken a just the get of discharge take weeks. emergency to anywhere which a the follow physicians promise like, currently up know scheduling call, that giving going we’ve six you to, they actually

So doesn’t feel patient necessarily well. make the

Jason Kolbert

it Yes, sense. makes

very… a like Sounds

Jon Hunt

right. important, That’s

Jason Kolbert

Right.

big launch also bit turned written what the where with very Can pragmatic questions and sounds into interaction a kind routine there planning You you on little that was the what’s FDA? about quickly, was real there it there a like like it’s response around like of sounds gone level did – were the high. surprises or stand It it’s talk were and just you a pretty confidence paced your of now? lot like given – any interaction Branislav pretty Sounds pretty it.

Branislav Vajdic

as as I comment process has who been to comment question. Jason Jon and also Yes. Thank to very you will close well. the for that

far So any surprises. seen not we have

waiting hour the et an next our point, lot little don’t end as response can we really And timing basically we step been has clearance went actually bit the received point, but and be, more spent the to that set cetera. around in terms of will half a of a step have FDA come We this this detail we Exact what FDA and with We are next know far are the a well impossible of under team, tail we right. at questions, for responded is as this stress, say, COVID, put tell. the will in confident that year. of At here.

But So action that don’t believe final know you. action be this we that’s additional we really light to the optimistic from by but sure year. for – the exact FDA, going maybe and Jon

Jon Hunt

FDA. we the questions was Yes. I back Well, one, – from think Jason got the

typically written questions, I we part think that’s the of is reviewers the my sometimes on phone of a we to is which part, it’s had because But turned I FDA. previously of some which wanted team’s think responses, as I’ve couple we a on in with call. experience preference review them dealing just And provide in that just misunderstanding right. the quickly, had the those around dispositioned the we then –

of sort to question. never to responding show indifference their You

responsive hosting interactive entire with with and provide with us, along minutes which in and And team my standpoint the the both were conference were that we review. responses, under think they reviews thing was call substantive had going a it’s the obviously said now FDA together. very pulled to them, promising meeting, the dialogue I we from reviewer to

the review you’re obviously, think my initial perspective. working promising been all post the remotely. from it’s timeline up that met as was their kept and they’ve COVID, fact statutory with is It’s still I this during aware, hammered on COVID. They’ve FDA

review said, have that the previously close close when Submissions want or are I difficult with review and to under the pin as they well. out. in to getting they them done try end. those Branislav substantive I’ve already experienced as year to queue and to and down get know very that tendency But a they’ll And that

from positive perspective. So my very

Jason Kolbert

you did to Yes, I release. so for press thank the that color. you laying way, And appreciate by Thank the milestones so clearly that. you helpful. the in see out as much. very It’s refreshing

Branislav Vajdic

Thank you Jason. questions, for your

Operator

[Operator take ahead. question Bill Benchmark next Instructions] Please from go The Sutherland Company. We’ll our from

now is line open. Your

Bill Sutherland

Hello that could Branislav, any additional on issued anticipating curious believe cover? in you. patents would front. roughly they so, quarter. team. type you near was area the they future? Great if be of intellectual you Thank here maybe I property the – the that would Are And

Branislav Vajdic

property intellectual of Apparently, strong this Very company. this rarely a this of foundation in portfolio is space, you and do range companies Yes. IP sort market that find you right. of in device growing, want this if cap a have

of So general, are at very common we It’s very say, not in this is I all. it. would – proud

Secondly, we my in is extremely of its commercial significant them Especially, of impact. one being own reviewed. in are meaningful impact, mind that have potential patents commercial a couple of terms

by under act, in year year certainly review predict preparation new the the they much the And filings, when end a the two to by they’re a in very as right. And property and of patent of going will days. significant One more out possible. of secondly, the the have continue we well. is then patent but generate we intellectual terms significant to few And of within is and approval a are FDA exactly hard end patent office

of rapid cadence continues a very at pace. the So IP

Bill Sutherland

expanded sets you’ve at as you really AIMIGos, at that of XX-lead. market the Do all to expect impact Great. And have you of focus? just you in the as the next types commercialization of solutions Or – two look the be two the your you it will go-to-market? real with same year, terms how – – process have

Branislav Vajdic

ahead. go please Jon,

Jon Hunt

Yes.

two it initially and knitting we them stick our AIMIGo. and presentation were, this as think will on in the to I AIMI described as it focus HeartBeam products

of keeping I the teams, one focused. commercial think people them challenges especially is with always sales

if and user get getting see we any feedback making like I those that all sort the clinicians, you established, them get the uptake for if things. early see running, early tweaks getting input of to the create or team, those for like the thing, from the So want what is the those adopters we pilots technical interface value

too little have I And jumbled at hopper get gets you too the message in if many we the once. go-to-market you if a think when scattered, bit things

So them got also and them be key an value boss I I think think with up some and inventor this we who’s that what I’ve get from they and when CEO want established how market my of on points may keeps established then the to platform. more to leverage get given, coming get feedback more the ideas

to So out I’m and spoiled the for team gate commercial but focused choice, sure. the of I for want keep

Bill Sutherland

December to you Discovery Got see all look our forward great it. Well, at Conference, Thanks. and X work.

Branislav Vajdic

Thank you, Bill.

Operator

[Operator Instructions] There at over questions are no webcast. this the time. move We’ll to further audio

Rick Brounstein

cover comment you difficult with companies Our you first easy companies insurance how had webcast be devices? can question asked, have to and on these discussions or it will to insurance get

Branislav Vajdic

go Jon, ahead. please

Jon Hunt

Yes.

companies. had with haven’t specific insurance We discussions

that with money span cardiovascular covered payers lot have very of on and well awful discussions to lots some large an connected control, lives payers the people of had the spend of their are of have that We large patients. care under

patients manage be with having of payers attractive. So much established for will we get market, discussion very those in where codes managing for risk technologies that for also like or example, I payers corresponding know higher I some the reimbursement those for high patients those is than patients, helping diabetic from reimbursement think the patients. once large to that patients manage

commercial actually insurance has got So been to an my with the of on one that’s think team on a discussion I we’re in order books make dent to a the in in patients. provide payer And company, managing demonstrate have. a to do the we a a run previous side to those to payer study need has the sorts and life value of studies will that certainly that

And something us. think So is on CPT mill. that’s it and is, removes of mind. definitely we for Code a attractive the a standard very yes, plan option actually our reimbursement from it on from revenue standpoint our sort us doing books I definitely But it’s

So want to those have and products then discussions. the approved get

Rick Brounstein

yet questions current questions be The asked how many to regarding And the submission? FDA has the asks, any next there XXX(k) question answered? are

Branislav Vajdic

Well, go we into going not detail… to are

Jon Hunt

that Branislav. I’ll Yes, take

Branislav Vajdic

questions …how thoroughly. many questions I’m all say asked, we answered not answered any indeed that many of into the But accurately us. And we at how they details, questions were let’s sure that very not going not aware questions. that number are of that just were this point, are remember

is, all by answer the questions by and the the action the… we we answered end are FDA have of So expecting

Rick Brounstein

question you retail to next diagnosis? a this use saving pharmacists in allow settings The asks, life provide to will technology

Branislav Vajdic

Jon, one. maybe answer this you should

Jon Hunt

and clinic mid-levels Walgreens setting, retail you’re and Walmart in or the minute assuming I’m equivalents. I as clinics lot well as minute of And CVS CVS staff clinics. their a by certainly region, know pharmacists thinking Charlotte Well, our of is these have in others that

to it’s discussion. that So potential have

I of the regarding because a us to a instances think people CVS’ hospital. I’d to a investigate CVS is I’m sure, of a in are are have country making on lot push clearly, world But they the than as are in the for a closer And of cardiac that back to further. the not potential interacting with are many – condition. they of pharmacists one cardiologists may diagnosis markets

patient proving clinical the It’s that how community So and something we a large. of see about do of one that’s to matter being go value providing that to at I the could tremendous value. also

I think a that pharmacist – got being study so. So make to it’s a field, the would to Again, the diagnoses that question. a into very want those something CVS realm or Walmart Walgreens even but conduct – allowing before interesting show value of in to or a

Rick Brounstein

if first more release for version webcast have not? that spring a not, question we release, AIMIGo the think one commercial and of next is question I time one and why is,

Branislav Vajdic

Jon think I the is that answer equipped to one. Again, best

Jon Hunt

Yes.

the of AIMIGo sort stripped basic a that, vector XD down you XD AIMIGo’s if version the indicated previously orthogonal, of heart. one recording that of at remember, the we’d version So is ECG

building the because landscape. create on goods one cost it at the XX-lead. So product information a to our version of a current the not provides core from us planning moment, for version given for And commercial moment. limited structure it’s the scalable we’re the we’re reimbursement a a But perspective, synthesized very and number at has one, high cost

and is reduced entire from where version of for which a scalable, have packaged we VX by everything because the dramatic goods we made and in one. And XX% labeled product behind, close drop so some it the the coming we’ve cost

very the patients. role going much a in for perspective set is and those a centers practice UI/UX, gather from the more of we’re clinical after full valuable at gate VX into information be in to to sort one clinical from these that moment can integrate launch, stage which then facilitate of VX us So identified at we’ve this out a to regulatory version launch as scalable at the fashion the horse to go clinical that we to product. going BAS work Look VX fill valuable will of and the that place put our scale systems with workflow, a product use for it aggressive healthcare

Operator

would conference over remarks. for like turn I closing now Vajdic the Mr. to to to over his back –

Branislav Vajdic

call today and you our Thank for you, update operator. earnings one progress joined to ongoing conference to I continuing and would on to each you forward our look growth. like thank us who of

IR will to who If day. your MZ please you have to Group, more were a questions, and out be you, of good answer assist. firm, our to than reach unable Thank any happy again

Operator

you participation. concludes for today’s your call. Thank This

You disconnect. may now

HeartBeam (BEAT) 10 Nov 222022 Q3 Earnings call transcript